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The design of heterologous prime-boost vaccine combinations that optimally shape
the immune response is of critical importance for the development of next generation
vaccines. Here, we tested different prime-boost combinations using the tuberculosis
vaccine antigen H56 with CAF01 or CpG ODN 1826 adjuvants, administered by the
parenteral and nasal routes. Using peptide-MHC class II tetramers, antigen-specific CD4+
T cells were tracked following primary and booster immunizations. Both parenteral priming
with H56 plus CAF01 and nasal priming with H56 plus CpG elicited significant expansion
of CD4+ tetramer-positive T cells in the spleen; however, only parenterally primed cells
responded to booster immunization. Subcutaneous (SC) priming with H56 and CAF01
followed by nasal boosting with H56 and CpG showed the greater expansion of CD4+
tetramer-positive T cells in the spleen and lungs compared to all the other homologous
and heterologous prime-boost combinations. Nasal boosting exerted a recruitment of
primed CD4+ T cells into lungs that was stronger in subcutaneously than nasally primed
mice, in accordance with different chemokine receptor expression induced by primary
immunization. These data demonstrate that SC priming is fundamental for eliciting CD4+
T cells that can be efficiently boosted by the nasal route and results in the recruitment
of antigen-experienced cells into the lungs. Combination of different vaccine formulations
and routes of delivery for priming and boosting is a strategic approach for improving and
directing vaccine-induced immune responses.
Keywords: CD4+ T cell priming, prime-boost strategies, MHC class II tetramers, CAF01, CpG, chemokines, lungs
Introduction
Heterologous combinations of vaccine formulations for priming and boosting the immune system
represent a strategic tool for the development of next generation vaccines. The combination of
vaccines including vectors or adjuvants with different mechanisms of action for priming and
boosting can contribute to the development of effective immune responses (1–6). In prime-boost
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vaccination strategies, different routes of delivery, such asmucosal
and parenteral, can also be combined in order to induce immune
responses in both the local and systemic compartments (7, 8).
A critical event in the initiation of the immune response to
vaccination is the primary activation of vaccine antigen-specific
T helper cells. T-cell priming indeed deeply influences both the
magnitude and the quality of the immune response elicited by
vaccination, as it is required for both the induction of high-affinity
antibodies and the generation of long-lasting immune memory
(9). Primary CD4+ T cell activation is therefore essential for
orchestrating the subsequent adaptive immune response elicited
by vaccination and its characterization in terms of magnitude,
quality, and memory generation, is therefore of primary impor-
tance in vaccine design (9). CD4+ T-cell priming properties of
different adjuvants (10–12), delivery systems (13, 14), and immu-
nization routes (15–17), have been characterized for a rational
design of effective prime-boost combinations (8). The route of
immunization deeply influences the local and systemic immune
response (18–20) and affects the polarization of CD4+ T effector
cells into different helper subtypes. We have recently shown that
the route used for priming but not for boosting, influences the Th1
or Th2 skewing, with a stronger Th1 polarization in mucosally
primed mice (8). Additionally, we have shown that mice primed
and/or boosted by the nasal route produce higher levels of IL-17A
than mice primed-boosted systemically. Moreover, local effector
responses are mainly dependent on mucosal boosting (8). There-
fore, the use of combined prime-boost immunization can impact
on the efficiency and the localization of the immune response to
a vaccine formulation.
Here, we assessed the antigen-specific local and systemic CD4+
T cell response following parenteral–mucosal prime-boost com-
binations, with the Mycobacterium tuberculosis fusion protein
H56 formulated with CAF01 or CpG ODN adjuvants. The fusion
protein H56 is a promising tuberculosis (TB) vaccine candidate
consisting of the antigens Ag85B fused to the 6-kDa early secre-
tory antigenic target (ESAT-6) and the latency-associated pro-
tein Rv2660c (21), and it is a component of vaccine candidates
currently in clinical trials (ClinicalTrials.gov Identifier numbers:
NCT01967134, NCT01865487). Adjuvants deeply influence the
quality of the adaptive immune response, and therefore, their
selection is fundamental in a vaccine formulation. Two vali-
dated adjuvants already tested in clinical trials (22, 23) and with
long pre-clinical track record were here selected for prime-boost
combinations. CAF01 adjuvant is a liposomal adjuvant system
composed of cationic liposome vesicles [dimethyldioctadecylam-
monium (DDA)] combined with a glycolipid immunomodulator
component [trehalose 6,6-dibehenate (TDB); a synthetic variant
of cord factor located in the mycobacterial cell wall] that act
in synergy to enhance vaccine-specific immune responses (24).
CAF01 has shown to promote vaccine depot formation, pro-
longing the release of antigens while targeting the antigens and
immunomodulator to the same activated APCs (25). Pre-clinical
studies with CAF01 have shown the induction of combined
Th1 and Th17 responses and generation of robust, long-lived
memory immunity (26, 27). We have recently characterized the
induction of primary antigen-specific CD4+ T responses elicited
by parenteral immunization with H56 and CAF01 confirming
the differentiation of primed CD4+ T cells into Th1 and Th17
subtypes together with follicular T helper cells within draining
lymph nodes (Prota et al., submitted). The other adjuvant selected,
CpG ODN 1826 (CpG), is an agonist of the toll-like receptor 9
(TLR9) andbelongs to the class of pathogens-associatedmolecular
patterns (PAMPs) that interact with different receptors present on
cells of the innate immune system (23). Several studies have shown
that the co-administration of CpG ODN with vaccines admin-
istered by mucosal routes significantly increases local antigen-
specific IgA and IgG levels systemically (23, 28, 29), and induces
primary CD4+ T cells responses in the draining lymph nodes and
in the spleens (10, 15). Clinical studies designed to evaluate CpG
activity in humans have shown its safety and adjuvanticity (23).
In the present study, we have characterized the induction
of antigen-specific CD4+ T-cell expansion and differentiation
elicited by priming or prime-boost combinations of vaccine for-
mulations, including H56 plus CAF01 or CpG adjuvants adminis-
tered by intra nasal (IN) or subcutaneous (SC) routes. Antigen-
specific T helper cells were identified employing MHC class II
tetramers complexedwith anAg85B-derived peptide that includes
an immunodominant epitope. Priming of Ag85B-specific CD4+
T cells was analyzed in the spleen and also in the lungs, the latter
representing the main target organ for local immune response
againstM. tuberculosis infection. These studies provide an impor-
tant contribution to the rational design of prime-boost combina-
tions capable of eliciting local and systemic antigen-specific CD4+
T cells.
Materials and Methods
Mice
Eight-week-old female C57BL/6 mice, purchased from Charles
River (Lecco, Italy) were maintained under specific pathogen-
free conditions at the University of Siena and treated according
to national guidelines (Decreto Legislativo 26/2014). All animal
studies were approved by the Ethics Committee “Comitato Etico
Locale dell’Azienda Ospedaliera Universitaria Senese” and the
Italian Ministry of Health (number 4/2011, on date 20/07/2011).
Immunizations
Subcutaneous immunizations were performed with theM. tuber-
culosis fusion protein H56 (22) (10μg/mouse, Statens Serum
Institut, Denmark) mixed with the adjuvant CAF01 (23) (250μg
DDA and 50μg TDB/mouse, Statens Serum Institut), in a volume
of 150μl/mouse of TRIS HCl 10μM. Nasal immunization was
performedwithH56 (10μg/mouse)mixed with the adjuvant CpG
ODN 1826 (20μg/mouse, TCC ATG ACG TTC CTG ACG TT,
Eurofins MWGOperon, Germany,) or with CAF01 (62.5μg DDA
and 12.5μg TDB/mouse), in a volume of 20μl/mouse of phos-
phate buffered saline solution (PBS, Sigma-Aldrich). For priming
studies, mice were immunized at day 0 and sacrificed on day 7,
while in prime-boost experiments, mice were immunized at day
0, boosted on week 4, and sacrificed 7 days later.
Sample Collection and Cell Preparation
Lungs and spleens were collected 7 days after primary or booster
immunization. Spleens were mashed onto nylon screens (Sefar
Italia, Italy) and washed two times in complete medium [RPMI
medium (Lonza, Belgium), 100U/ml penicillin/streptomycin, and
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10% fetal bovine serum (GIBCO, USA)]. Lungs were collected
as previously described (13), briefly after in vivo perfusion with
PBS, organs were digested with collagenase D (1mg/ml, Sigma-
Aldrich) and DNase I (28U/ml, Sigma-Aldrich) enzymes for 1 h
at 37°C,mashed on nylon screens, and separated on lympholyteM
cell separation density gradient centrifugation media (Cedarlane
Laboratories, Canada).
Flow Cytometric Analysis
Cells were seeded (5 106 cells/well) in a V-bottom 96-well plate
(SARSTED, USA) and incubated for 30min at 4°C in Fc-blocking
solution [complete medium plus 5μg/ml of CD16/CD32 mAb
(clone 93; ebioscience, CA, USA)]. PE-conjugated I-A(b) M.
tuberculosisAg85B precursor 280-294 (FQDAYNAAGGHNAVF),
or PE-conjugated human class II-associated invariant chain pep-
tide (PVSKMRMARPLLMQA) tetramers (NIH MHC Tetramer
Core Facility, Emory University, Atlanta, GA, USA) were added at
the concentration of 15μg/ml. Samples were washed and stained
on ice with PE-CY7-conjugated anti-CXCR3 (clone CXCR3-73),
BV421-conjugated anti-CCR6 (clone 292L17, all purchased from
Biolegend, CA, USA), HV500-conjugated anti-CD4 (clone RM4-
5), and HV450-conjugated anti-CD44 (clone IM7, all purchased
from BD biosciences, CA, USA). Samples were labeled with
LIVE/DEAD Fixable Near IR Dead Cell Stain Kit according to the
manufacturer instruction (Invitrogen, USA). Intracellular stain-
ing for BV605-conjugated anti-T-bet (clone 4b10, Biolegend, CA,
USA) and PerCPCY5.5-conjugated anti-RORγt (clone Q31-378)
(BD biosciences, CA, USA) was performed using the Foxp3 stain-
ing buffer set (eBioscience, CA, USA) according to the manu-
facturer instruction. Antibodies and tetramers were titrated for
optimal dilution. About 106 cells were stored for each sample
acquired onLSR II flow cytometer (BDbiosciences), anddatawere
analyzed with FlowJo (TreeStar, OR, USA).
Statistical Analysis
One-way ANOVA and Tukey’s post test for multiple comparisons
were employed to analyze frequencies of Ag85B-specific CD4+
T cells between groups receiving the same primary immuniza-
tion and to analyze frequencies of Ag85B-specific CD4+ T cells
detected in naïve mice and in groups only primed. Two-tailed
Student’s t-test was employed to analyze statistical differences
between the percentage of Ag85B-specific CD4+ T cells express-
ing transcription factors and chemokines receptors, in the two
groups selected. Statistical significance was defined as P 0.05.
Graphpad 4.0 software was used for analysis.
Results
Ag85B-Specific CD4+ T Cell Response in the
Spleen Following Different Prime-Boost
Combinations
Antigen-specific T helper responses were evaluated following
heterologous prime-boost immunizations obtained with the two
adjuvants CAF01 and CpG and parenteral/mucosal delivery
routes. CD4+ T cells specific for the immunodominant epitope
of Ag85, that is part of the H56 fusion protein, were identified
using Ag85B280–294-complexedMHC class II tetramers. Tetramer-
binding CD4+ (Tet+) T cells were assessed in spleens 7 days after
primary or secondary immunizations. Representative dot plots
showing Tet+ T cells frequency in immunized or naïve animals
are shown in Figure 1A. Staining specificity was determined using
a control tetramer complexed with an unrelated antigen that
showed a level of staining below 0.02% (data not shown).
In Figure 1B, frequencies of Tet+ T cells detected in naïve
mice (inverted triangles) or elicited by priming (circles) or prime-
boost combination (diamonds, squares, or triangles) are reported.
Priming with both CAF01 by the SC route (black circles) and CpG
by the IN route (open circles) induced a significant increase of
Tet+ T cell frequency compared to naïve animals (open inverted
triangles, P 0.001), while CAF01 administered by the IN route
was not effective in stimulating antigen-specific T-cell priming
(gray circles).
Mice SC primed with H56 and CAF01 generated stronger
peptide-specific CD4+ T cell responses following booster immu-
nizations compared to nasally primed mice. Indeed, primed cells
were efficiently boosted by both SC immunization with CAF01
(black diamonds) and IN administration of CpG (black triangles)
with a significant increase of T-cell responses compared to the
group parenterally primed with CAF01 (P 0.01 and P 0.001,
respectively). IN boosting with CAF01 improved the frequency
of Tet+ T cells (black squares), but the increase was not statisti-
cally significant compared to primed mice using the analysis of
variance test.
Animals primed by the IN route with the two adjuvants CAF01
andCpGwere low responders to booster immunization compared
to parenterally primed mice. Indeed, although the frequency of
Tet+ T cells induced by IN administration of CpG (open circles)
was similar to the one observed upon SC priming with CAF01
(black circles) these T cells could not be boosted, as shown by the
very low frequencies of Tet+ T cells upon booster immunizations
(Figure 1B). The expansion detected in nasally primedmice upon
SC boosting with CAF01 (gray and white diamonds) resembled
the primary response elicited by parenteral priming with CAF01
(black circles), suggesting that the observed response couldmerely
be a result of the parenteral immunization.
Since the relative frequency of Tet+ respect to total CD4+ T
cells can be affected by the enhancement of total CD4+ T cells
upon boosting, we also analyzed the absolute number of Ag85B-
specific CD4+ T cells within the spleen. The higher increase of
Tet+ T cell number in the spleens upon booster immunization
was observed in mice that had been parenterally primed with
CAF01 and nasally boosted, but not in groups nasally primed
(Figure 1C).
Ag85B-Specific CD4+ T Cell Response in Lungs
Following Different Vaccine Combinations
Expansion of Ag85B-specific CD4+ T cells was analyzed in
lungs, a target effector site for vaccines aimed at fighting airway
pathogens. Primary immunization by SC route with CAF01 (black
circles, 0.4%) and IN route with CpG (open circles, 0.3%), but not
CAF01 (gray circles) induced a significant increase of Tet+ T cell
frequency compared to naïve animals (open triangles, P 0.001
and P 0.05, respectively). As observed in the spleen, parenter-
ally primed-mucosally boosted mice showed the stronger Tet+ T
cell response compared to the other combinations, highlighting
the recruitment effect exerted by the nasal route employed for
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FIGURE 1 | Ag85B-specific CD4+ T cells in the spleen of mice
immunized with different prime-boost combinations. (A) Representative
dot plots showing the identification of Ag85-specific T helper cells in immunized
or naïve mice. Tet+ T cells were detected as CD44high Tet-Ag85B+ cells gated
on live CD4+ lymphocytes; percentages of Tet+ T cells respect to CD4+ T cells
are reported. (B) Tet+ T cells in the spleen of mice primed (week 0) and boosted
(week 4) with different vaccine combinations administered by parenteral or
mucosal routes and assessed 7days after the last immunization. The analysis
shows the percentage of Tet+ T cells detected in the spleen of naïve mice (open
inverted triangles), primed groups (black, gray and white circles), or prime-boost
groups (diamonds, squares, and triangles). Vaccine combinations include
parenteral priming with CAF01 followed by parenteral or nasal boosting with
CAF01 or CpG (filled symbols), nasal priming with CAF01 followed by parenteral
or nasal boosting with CAF01 (gray symbols), or nasal priming with CpG
followed by parenteral or nasal boosting with CAF01 or CpG (open symbols).
Statistical analysis was performed using one-way ANOVA and Tukey’s post test
for multiple comparisons among groups receiving the same primary
immunization (*P0.05, **P0.01, and ***P0.001) as well as among mice
receiving only the primary immunization versus naïve animals (#P0.05).
(C) Absolute number of Tet+ T cells in the spleen, elicited by priming or
prime-boost combinations, reported as meanSEM of 6–12 animals per group
from two independent experiments. Statistical analysis was performed using
one-way ANOVA and Tukey’s post test for multiple comparisons among groups
receiving the same primary immunization (*P0.05) as well as among mice
receiving only the primary immunization (#P0.05 versus SC priming with
CAF01 and IN priming with CpG).
boosting (Figure 2A). The highest percentage of Tet+ T cells was
observed in mice parenterally primed with CAF01 and nasally
boosted with CpG (black triangles) that was about 5% of CD4+ T
cells of the lungs, while about 3% were detected upon IN boosting
with CAF01 (black, squares). An increase in the frequency of Tet+
T cells was observed also in the group subcutaneously boosted
with CAF (black diamonds), although not statistically significant
(Figure 2A).
Cells primed by the IN route with both CAF01 and CpG were
much less prone to expand upon nasal boosting compared to
parenterally primed cells (Figure 2A). This was clearly shown by
the absolute number of antigen-specific CD4+ T cells found in the
lungs that highlights the strong increase in parenterally primed-
nasally boosted mice (both with CAF01 and CpG) compared to
the other prime-boost combinations (Figure 2B). The stronger
recruitment of tetramer-specific CD4+ T cells into lungs upon
IN boosting correlated with a high afflux of total lymphocytes
into the organs (data not shown). This analysis shows not only
the recruitment effect exerted by IN boosting but also the funda-
mental role of primary immunization in generating cells capable
of reactivating upon secondary immunization.
In conclusion, parenteral priming with CAF01 adjuvant fol-
lowed by nasal boosting with CpG was the prime-boost com-
bination that elicited the stronger peptide-specific CD4+ T cell
response in both spleen and lungs.
Phenotypic Characterization of Tet+ T Cells
Elicited by Nasal or Parenteral Priming and
Boosted by IN Route
The analysis of Tet+ T cells in the lungs highlighted the important
role of the IN route for boosting, and the different recruitment
effect exerted on cells that had been primed by parenteral or nasal
immunizations. We therefore investigated if Tet+ T cells, elicited
by IN immunization with CpG or SC immunization with CAF01
and then boosted with CpG by the nasal route, showed differ-
ences in terms of subtype differentiation and chemokine receptor
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FIGURE 2 | Ag85B-specific CD4+ T cells in the lungs of mice immunized
with different prime-boost formulations. (A) Tet+ T cells in the lungs of
mice primed (week 0) and boosted (week 4) with different vaccine combinations
administered by parenteral or mucosal routes and assessed 7days after the last
immunization. The analysis shows the percentage of Tet+ T cells detected in
lungs of naïve mice (open inverted triangles), primed groups (black, gray, and
white circles), or prime-boost groups (diamonds, squares, and triangles).
Vaccine combinations included parenteral priming with CAF01 followed by
parenteral or nasal boosting with CAF01 or CpG (filled symbols), or nasal
priming with CAF01 followed by parenteral or nasal boosting with CAF01 (gray
symbols), or nasal priming with CpG followed by parenteral or nasal boosting
with CAF01 or CpG (open symbols). Statistical analysis was performed using
One-way ANOVA and Tukey’s post test for multiple comparisons among groups
receiving the same primary immunization (*P0.05, **P0.01, and
***P0.001) as well as among mice receiving only the primary immunization
versus naïve animals (#P0.05). (B) Absolute number of Tet+ T cells in lungs
elicited by priming or prime-boost combinations reported as meanSEM of
6–12 animals per group from 2 to 3 independent experiments.
expression. Both adjuvants are known to stimulate Th1 subtype
differentiation (26, 30) while Th17 had been reported with CAF01
(27), we therefore analyzed the intracellular expression of T-bet
and RORγt, the respective master transcription factors (31, 32)
among Tet+ T cells. Frequency of T-bet-positive cells was signifi-
cantly higher in the spleen of parenterally primed-nasally boosted
mice compared to mucosally primed-boosted animals, while in
the lungs, both T-bet and RORγt positive cells were observed
without significant differences between the two vaccination strate-
gies (Figure 3A). We therefore assessed if Tet+ T cells recruited
into lungs in parenterally primed-nasally boosted mice expressed
different chemokine receptors with respect to the nasally primed-
boosted group. In the first group, there was a higher percentage of
Tet+ T cells that expressed CXCR3 (Figure 3B) with a significant
higher intensity (Figure 3C) compared to the mucosally primed-
boosted group, which in turn showed a higher expression of CCR6
(Figure 3B). The expression of CXCR3 or CCR6 in lung cells
was not dependent on the T cell subtype, since no significant
differences were observed among T-bet+ and RORγt+ subgroups
(data not shown).
In conclusion, the different recruitment of peptide-specific
CD4+ T cells into lungs elicited by the two immunization strate-
gies could be due to the different chemokine receptors expressed
by T cells upon primary activation.
Discussion
The induction of primary and secondary peptide-specific CD4+
T cell responses was assessed and compared following different
prime-boost immunization strategies based on the combinations
of different vaccine formulations and routes of delivery. Our
data show that parenteral priming with H56 antigen and CAF01
adjuvant followed by nasal boosting with vaccine antigen and
CpG is the prime-boost combination able to elicit the strongest
peptide-specific CD4+ T cell response in both spleen and lungs,
compared to the other homologous or heterologous prime-boost
combinations tested.
Parenteral priming with CAF01 adjuvant elicited the highest
number of antigen-specific CD4+ T cells capable of responding
to booster immunization, whereas the T cell response detected
after nasal priming was poorly responsive to recall immunization.
While nasal priming with CAF01 did not induce proliferation
of Tet+ T cells, suggesting that CAF01 is not optimal for CD4+
T cell priming by the IN route, nasal priming with the CpG
adjuvant elicited a significant expansion of Ag85B-specific CD4+
T cells that, in terms of absolute numbers and frequency of primed
cells, was comparable to that observed in parenterally primed
mice. Nevertheless, these primed CD4+ T cells did not respond
to both homologous and heterologous secondary immunization,
suggesting thatmemory cells were not efficiently elicited by the IN
priming. The low capacity of nasal priming to generate booster
responder CD4+ T cells was noted with both CAF01 and CpG
adjuvants that differ in structure andmechanismof action, being a
liposomal adjuvant system incorporating the C-type lectinMincle
agonist TDB and a pure TLR9 ligand, respectively. This obser-
vation demonstrates that different conditions of primary immu-
nization differently affect the immunological memory process, an
event shaped by many factors that still needs to be understood in
its complexity. A critical factor may be the timing of antigen pre-
sentation; indeed, it has been recently shown that effector CD4+ T
cells need a late contact with antigen presenting cells 4–6 days after
immunization to survive to the contraction phase and generate a
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FIGURE 3 | Phenotypic analysis of Tet+ T cells detected in spleen
and lungs. Tet+ T cells detected in spleens and lungs of mice primed by
SC route with CAF01 or by IN route with CpG and nasally boosted with
CpG were characterized for the expression of transcription factors (A) and
CXCR3 and CCR6 chemokine receptors (B,C). (A) Percentage of RORγt
(filled bars) and T-bet (empty bars) positive cells among tetramer-binding
CD4+ T cells detected in mice immunized with the vaccine combinations
are reported in x axis. (B,C) Percentage (B) and mean fluorescent intensity
[MFI, (C)] of CXCR3-positive (gray bars) and CCR6-positive cells (striped
bars) among Tet+ T cells assessed in lungs of mice immunized with the
vaccine combinations are reported in x axis. Bars represent the
meanSEM of six mice per group and it is representative of two
independent experiments. Statistical analysis was performed using the
two-tailed Student’s t-test. *P<0.05, **P<0.01.
pool of memory CD4+ T cells (33). We previously characterized
within draining lymph nodes the antigen presentation of a fluo-
rescent model antigen administered with CpG by the IN route,
showing that the presentation peaked 12 h after immunization
and was completely exhausted within 3 days (15). This is different
from parenteral immunization with a vaccine antigen and CAF01,
where the duration of antigen presentation was at least 5 days
(25). However, other mechanisms, such as local innate immune
responses, costimulatory and cytokine signals during the antigen
presentation event, different recirculation of primed T cells, can
differently influence the immunological memory process upon
systemic and mucosal priming.
IN immunization with both CAF01 and CpG adjuvants was
able to stimulate a recall response to parenterally primed mice.
Indeed, nasal boosting was essential for the recruitment in the
lungs of activated CD4+ T cells. The optimal prime-boost combi-
nation for eliciting activated CD4+ T cells, not only in the spleen
but also in the lungs, appeared to be parenteral priming with
CAF01 followed by nasal boosting with CpG. The dissemination
of Ag-specific CD4+ T cells in the lungs elicited by nasal booster
immunization was largely dependent on the T-cell priming event.
Indeed, parenterally primed-nasally boosted mice exhibited more
than a 100-fold increase in the amount of Ag85B-specific CD4+ T
cells in the lungs upon secondary immunization, while the recruit-
ment of specific CD4 T cells after mucosal boosting was extremely
low in nasally primed mice. This behavior was not due to a dif-
ferent subpopulation profile generated during the priming event
by CAF01 or CpG, since primed CD4+ T cells differentiated into
similar T helper subtypes that expressed T-bet or RORγt, without
significant differences between the two vaccine formulations. On
the contrary, different chemokine receptors were induced on the
surface of Tet+ T cells primed by parenteral or nasal routes.
CXCR3, known to be involved in lung trafficking of T cells (34),
was expressedmore highly on parenterally thanmucosally primed
Tet+ T cells, which in turn expressed more CCR6, a marker
associated with Th17 and IL-17 secretion (35). Therefore, the
pattern of chemokine receptors appears to be differently regulated
on cells primed by SC or IN route, and this can influence the
cell migration. These data are particularly relevant when vaccines
able to induce local immune responses are required. Indeed, the
generation of pulmonary antigen-specific CD4+ T cells is of key
importance for the design of TB vaccines aimed at inducing local
immune responses in the respiratory tract (36, 37). Of course, the
recruitment of immune cells into lungs needs to be tightly regu-
lated to effectively favor protective mechanisms while avoiding or
minimizing immunopathology (37). This is a crucial aspect in the
field of TB vaccine development, which has been complicated and
delayed by major gaps in the understanding of how immunity to
TB manifests itself at the site of infection in the lung (38).
Despite many potential advantages of mucosal administration
of vaccines, today only a few vaccines are licensed for nasal or oral
administration (39–41). Heterologous combinations of adminis-
tration routes offer the possibility of generating local immune
response, using the mucosal route for boosting cells previously
primed by the parenteral route.
In the current study, no severe adverse effects indicative of
immunopathology in the respiratory tract of parenterally primed
and nasally boosted mice were observed, beyond an increase in
total T cell numbers in the lung. However, more detailed examina-
tion of airway responsiveness in future models would be required
to absolutely determine the safety of this prime-boost approach.
In conclusion, our data show the induction of an efficientCD4+
T cell priming upon SC, but not IN administration of CAF01
with generation of cells that can be efficiently boosted by both
parenteral and nasal routes. On the contrary, IN priming with
both CAF01 and CpG adjuvants did not elicit cells capable of
reactivation upon booster immunization. The stronger CD4+ T
cell activation in both spleen and lungs was induced by parenteral
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priming with H56 and CAF01 followed by nasal boosting with
vaccine antigen and CpG, compared to the other homologous
or heterologous prime-boost combinations tested. These data
demonstrate that parenteral priming followed by nasal boosting
induces CD4+ T cell responses in lungs and spleen. Priming
and booster immunization are therefore strategic events in the
induction of vaccine immune responses, and the choice of adju-
vants or vectors together with the route of immunization plays
a fundamental role for improving vaccine immunogenicity and
directing the recruitment of antigen-specific cells into specific
effector sites, such as the lungs.
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